blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2797898

EP2797898 - PIPERAZINYL DERIVATIVES FOR THE TREATMENT OF CANCERS [Right-click to bookmark this link]
Former [2014/45]PIPERAZINYL DERIVATIVES FOR THE TREATMENT OF CANCER
[2015/45]
StatusNo opposition filed within time limit
Status updated on  21.07.2017
Database last updated on 19.10.2024
Most recent event   Tooltip23.04.2021Correction of patent specificationpublished on 26.05.2021  [2021/21]
Applicant(s)For all designated states
Pitty, Marc-Henry
31 Avenue JB Clément
92100 Boulogne - Billancourt / FR
[2014/45]
Inventor(s)01 / CARNIATO, Denis
33, avenue du Maréchal de Lattre de Tassigny
91460 Marcoussis / FR
02 / BRIAND, Jean-François
2 bis rue de Palaiseau
91400 Saclay / FR
03 / GUTMANN, Mathieu
14, rue du Bois Gaillard
91640 Vaugrigneuse / FR
04 / BUSNEL, Olivier
8, rue de l'Enclos
59251 Allennes les Marais / FR
05 / BOUGERET, Cécile
26, rue du Cloître Saint-Cyr
58000 Nevers / FR
06 / DEPREZ, Benoit
19, rue des célistines
59000 Lille / FR
07 / JAILLARDON, Karine
22, rue des Dragons
91240 Saint Michel s/Orge / FR
 [2016/37]
Former [2014/45]01 / CARNIATO, Denis
33 avenue du Maréchal de Lattre de Tassigny
F-91460 Marcoussis / FR
02 / BRIAND, Jean-François
2 bis rue de Palaiseau
F-91400 Saclay / FR
03 / GUTMANN, Mathieu
14 rue du Bois Gaillard
F-91640 Vaugrigneuse / FR
04 / BUSNEL, Olivier
8 rue de l'Enclos
F-59251 Allennes les Marais / FR
05 / BOUGERET, Cécile
26 rue du Cloître Saint-Cyr
F-58000 Nevers / FR
06 / DEPREZ, Benoit
19 rue des célistines
F-59000 Lille / FR
07 / JAILLARDON, Karine
22 rue des Dragons
F-91240 Saint Michel s/Orge / FR
Representative(s)Regimbeau
20, rue de Chazelles
75847 Paris Cedex 17 / FR
[2014/45]
Application number, filing date12808851.528.12.2012
[2016/37]
WO2012EP77059
Priority number, dateFR2011006258630.12.2011         Original published format: FR 1162586
[2014/45]
Filing languageFR
Procedural languageFR
PublicationType: A1 Application with search report
No.:WO2013098393
Date:04.07.2013
Language:FR
[2013/27]
Type: A1 Application with search report 
No.:EP2797898
Date:05.11.2014
Language:FR
The application published by WIPO in one of the EPO official languages on 04.07.2013 takes the place of the publication of the European patent application.
[2014/45]
Type: B1 Patent specification 
No.:EP2797898
Date:14.09.2016
Language:FR
[2016/37]
Type: B9 Corrected patent specification 
No.:EP2797898
Date:26.05.2021
[2021/21]
Search report(s)International search report - published on:EP04.07.2013
ClassificationIPC:C07D241/04, C07D409/06, C07D487/04, C07D487/08, A61K31/4965, A61P35/00
[2014/45]
CPC:
C07D487/08 (EP,CN,RU,US); C07D241/04 (EP,CN,RU,US); C07D409/06 (EP,CN,RU,US);
A61K31/495 (EP,RU,US); A61K31/496 (EP,RU,US); A61K31/4985 (EP,US);
A61K45/06 (US); A61P35/00 (EP); A61P43/00 (EP);
C07D487/04 (EP,CN,RU,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/45]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:PIPERAZINYL-DERIVATE FÜR DIE BEHANDLUNG VON KREBS[2015/45]
English:PIPERAZINYL DERIVATIVES FOR THE TREATMENT OF CANCERS[2015/45]
French:DERIVES PIPERAZINYLES POUR LE TRAITEMENT DE CANCERS[2014/45]
Former [2014/45]PIPERAZINYLDERIVATE ZUR BEHANDLUNG VON KREBS
Former [2014/45]PIPERAZINYL DERIVATIVES FOR THE TREATMENT OF CANCER
Entry into regional phase23.07.2014National basic fee paid 
23.07.2014Designation fee(s) paid 
23.07.2014Examination fee paid 
Examination procedure23.07.2014Examination requested  [2014/45]
26.02.2015Amendment by applicant (claims and/or description)
22.05.2015Communication of intention to grant the patent
22.09.2015Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
19.10.2015Communication of intention to grant the patent
24.02.2016Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
15.03.2016Communication of intention to grant the patent
20.07.2016Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
20.07.2016Fee for grant paid
20.07.2016Fee for publishing/printing paid
09.08.2016Information about intention to grant a patent
09.08.2016Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  22.05.2015
Opposition(s)15.06.2017No opposition filed within time limit [2017/34]
Fees paidRenewal fee
10.12.2014Renewal fee patent year 03
08.12.2015Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL14.09.2016
AT14.09.2016
CY14.09.2016
DK14.09.2016
EE14.09.2016
FI14.09.2016
HR14.09.2016
LT14.09.2016
LV14.09.2016
MK14.09.2016
MT14.09.2016
RO14.09.2016
RS14.09.2016
SI14.09.2016
SK14.09.2016
SM14.09.2016
BG14.12.2016
NO14.12.2016
GR15.12.2016
IS14.01.2017
PT16.01.2017
[2018/47]
Former [2018/43]AT14.09.2016
CY14.09.2016
DK14.09.2016
EE14.09.2016
FI14.09.2016
HR14.09.2016
LT14.09.2016
LV14.09.2016
MK14.09.2016
MT14.09.2016
RO14.09.2016
RS14.09.2016
SI14.09.2016
SK14.09.2016
SM14.09.2016
BG14.12.2016
NO14.12.2016
GR15.12.2016
IS14.01.2017
PT16.01.2017
Former [2018/31]AT14.09.2016
CY14.09.2016
DK14.09.2016
EE14.09.2016
FI14.09.2016
HR14.09.2016
LT14.09.2016
LV14.09.2016
MK14.09.2016
RO14.09.2016
RS14.09.2016
SI14.09.2016
SK14.09.2016
SM14.09.2016
BG14.12.2016
NO14.12.2016
GR15.12.2016
IS14.01.2017
PT16.01.2017
Former [2017/52]AT14.09.2016
DK14.09.2016
EE14.09.2016
FI14.09.2016
HR14.09.2016
LT14.09.2016
LV14.09.2016
RO14.09.2016
RS14.09.2016
SI14.09.2016
SK14.09.2016
SM14.09.2016
BG14.12.2016
NO14.12.2016
GR15.12.2016
IS14.01.2017
PT16.01.2017
Former [2017/34]AT14.09.2016
DK14.09.2016
EE14.09.2016
FI14.09.2016
HR14.09.2016
LT14.09.2016
LV14.09.2016
RO14.09.2016
RS14.09.2016
SK14.09.2016
SM14.09.2016
BG14.12.2016
NO14.12.2016
GR15.12.2016
IS14.01.2017
PT16.01.2017
Former [2017/32]AT14.09.2016
EE14.09.2016
FI14.09.2016
HR14.09.2016
LT14.09.2016
LV14.09.2016
RO14.09.2016
RS14.09.2016
SK14.09.2016
SM14.09.2016
BG14.12.2016
NO14.12.2016
GR15.12.2016
IS14.01.2017
PT16.01.2017
Former [2017/13]FI14.09.2016
HR14.09.2016
LT14.09.2016
LV14.09.2016
RS14.09.2016
NO14.12.2016
GR15.12.2016
Former [2017/11]FI14.09.2016
HR14.09.2016
LT14.09.2016
RS14.09.2016
NO14.12.2016
GR15.12.2016
Former [2017/10]FI14.09.2016
HR14.09.2016
LT14.09.2016
RS14.09.2016
NO14.12.2016
Former [2017/09]FI14.09.2016
LT14.09.2016
NO14.12.2016
Former [2017/07]LT14.09.2016
Cited inInternational search[ID]WO2009150248  (CYTOMICS SYSTEMS [FR], et al) [ID] 1-17 * examples 3-6; claims 1,3-10; compounds 198,200,201,203,206 *;
 [AP]WO2012009678  (AGIOS PHARMACEUTICALS INC [US], et al) [AP] 1-17* page 5, lines 1-14; example 12; claims 5,12; compounds 118,185,190 *
by applicantWO2009150248
    - BAGULEY, MOL. BIOTECHNOL., (2010), vol. 46, pages 308 - 316
    - GATTI ET AL., METHODS MOL. MED., (2005), vol. 111, pages 127 - 148
    - LONGLEY ET AL., J. PATHOL., (2005), vol. 205, pages 275 - 292
    - KOHNO ET AL., EUR. J. CANCER, (2005), vol. 41, pages 2577 - 2586
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.